Japanese encephalitis vaccine, JEVAL, to be marketed in Taiwan

Valneva SE, a leading pure play vaccine company, announced today that vaccine manufacturer Adimmune was granted marketing approval for Valneva's Japanese encephalitis (JE) vaccine by the Taiwanese Food & Drug Administration (TFDA). The product is expected to be marketed in Taiwan under the trade name JEVAL(R) . This approval follows the agreement signed in 2014 ["]